OBJECTIVES: Cervical cancer is the third most common cancer and the fourth cancer cause of death in women in Brazil. Given the high incidence, this disease has a considerable financial impact in the health budget. The study objective is to develop a cost-of-illness study to measure the cervical cancer social cost based in secondary data available for public access, in Brazil. METHODS: The total cervical cancer social cost was calculated including direct medical costs (outpatient and inpatient), non-medical costs (caregiver day hospital), productivity loss due to inability of the patient to work, potential life-years lost and income loss due to premature death. Annual medical and non-medical costs were extracted from Brazilian official database (DATASUS) based on the average annual costs of the last tree years (2012-2014). Inpatient productivity loss was calculated considering the mean length of stay reported in DATASUS and the Brazilian minimum wage. Outpatient productivity loss was calculated considering that patient would take one to fifteen days off. Income loss due to premature death was measured subtracting the Brazilian life expectancy by the age of death, also reported in DATASUS, and multiplying by the Brazilian annual average wage reported by Brazilian Institute of Geography and Statistics. International Classification of Diseases (ICD-10) codes considered in this analysis wereC358 and C359. RESULTS: Cervical cancer annual direct and indirect cost is BRL 71 millions (outpatient cost: BRL44,608,394; inpatient cost including caregiver day hospital: BRL23,697,642; productivity loss (range): BRL7,880,390-BRL20,146,696). Besides, BRL917 million was annually spent with income loss due to premature death. The total potential life-years lost was estimated in 33.898 years. CONCLUSIONS: The results reveal that the cervical cancer cost is high in Brazil. Despite these results presented are an approximation of the real disease cost, it can be a useful data to improve health management practices and public policies.